1. Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease.
- Author
-
Spekhorst LM, Imhann F, Festen EAM, van Bodegraven AA, de Boer NKH, Bouma G, Fidder HH, d'Haens G, Hoentjen F, Hommes DW, de Jong DJ, Löwenberg M, Maljaars PWJ, van der Meulen-de Jong AE, Oldenburg B, Pierik MJ, Ponsioen CY, Stokkers PC, Verspaget HW, Visschedijk MC, van der Woude CJ, Dijkstra G, and Weersma RK
- Subjects
- Adult, Female, Genotyping Techniques, Humans, Inflammatory Bowel Diseases therapy, Male, Netherlands epidemiology, Prospective Studies, Young Adult, Biological Specimen Banks, Disease Progression, Inflammatory Bowel Diseases classification, Inflammatory Bowel Diseases genetics
- Abstract
Purpose: The Dutch IBD Biobank aims to facilitate the discovery of predictors for individual disease course and treatment response in patients with inflammatory bowel disease (IBD). In this paper, we aim to describe the establishment of the Dutch IBD Biobank, including the facilitators and barriers to establishment. Moreover, we aim to provide a complete overview of the content of the Dutch IBD Biobank., Participants: Since 2007, every patient with IBD treated in one of the eight Dutch university medical centres is asked to participate in the Dutch IBD Biobank in which 225 standardised IBD-related data items and biomaterials, such as serum, DNA, biopsies and a stool sample, are collected., Findings to Date: As of June 2014, the Dutch IBD Biobank had enrolled 3388 patients with IBD: 2118 Crohn's disease (62.5%), 1190 ulcerative colitis (35.1%), 74 IBD-unclassified (2.2%) and 6 IBD-indeterminate (0.2%). The inclusion of patients with IBD is ongoing. The quality of the biomaterials is good and serum, DNA and biopsies have been used in newly published studies., Future Plans: The genotyping (750 000 genetic variants) of all participants of the Dutch IBD Biobank is currently ongoing, enabling more genetic research. In addition, all participants will start reporting disease activity and outcome measures using an online platform and mobile app ., Competing Interests: Competing interests: FI reports personal fees for speaking from AbbVie. AAvB reports personal fees for consultation or speaking from AbbVie, Ferring, MSD, Takeda, Tramedico and VIFOR, he is member of the Committee on Drugs of the Dutch Society for Gastroenterology (NVMDL). RKW reports unrestricted research grants from Ferring and Tramedico, and personal fees during the conduct of the study from Abbott but outside the submitted work. AEvdMdJ reports unrestricted research grants from Takeda and Abbott, and personal fees during the conduct of the study from Abbott, Takeda and Tramedico outside the submitted work. NKHdB reports unrestricted research grant from FALK outside the submitted work, personal fees for consultation or speaking from AbbVie and Teva Pharma, and he is a member of the Advisory Board of MSD., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2017
- Full Text
- View/download PDF